Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Celgene
Celgene
The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)
Yahoo/Motley Fool
Fri, 06/28/19 - 10:14 am
Bristol-Myers Squibb
Celgene
M&A
BeiGene
tislelizumab
Otezla
Bristol-Myers Squibb: Losing Otezla Might Be Challenging
Market Realist
Tue, 06/25/19 - 09:28 am
Bristol-Myers Squibb
Celgene
M&A
Otezla
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
Mon, 06/24/19 - 07:27 pm
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later
Endpoints
Mon, 06/24/19 - 11:23 am
Bristol-Myers Squibb
Opdivo
Otezla
M&A
FTC
Celgene
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
Fri, 06/21/19 - 11:24 am
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?
Motley Fool
Thu, 06/20/19 - 10:49 am
Bristol-Myers Squibb
Celgene
M&A
Meet the Top Ten Drugs of 2024 (Maybe)
Drug Channels
Tue, 06/18/19 - 11:46 pm
AbbVie
Humira
Merck
Keytruda
Eliquis
Bristol-Myers Squibb
Imbruvica
Opdivo
Revlimid
Celgene
As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup
Endpoints
Mon, 06/17/19 - 10:06 am
BeiGene
Bristol-Myers Squibb
Celgene
Opdivo
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Wed, 06/12/19 - 09:45 am
Vertex Pharmaceuticals
VX-445
tezacaftor/ivacaftor
AbbVie
upadacatinib
Daiichi Sankyo
trastuzumab deruxtecan
Celgene
liso-cel
Novartis
LY3298176
Grail’s Cook Steps Down, Former Juno Executive Bishop Named CEO
BioCentury
Thu, 06/6/19 - 10:37 pm
Grail
diagnostics
Juno Therapeutics
Celgene
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Endpoints
Thu, 06/6/19 - 09:53 am
Celgene
FDA
EMA
ozanimod
multiple sclerosis
BMS reveals its post-Celgene takeover management team
Pharmaforum
Thu, 06/6/19 - 09:30 am
Bristol-Myers Squibb
Celgene
M&A
In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful
Fierce Biotech
Tue, 06/4/19 - 11:02 am
Celgene
Bristol-Myers Squibb
Acceleron
luspatercept
MDS
beta thalassemia
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury
Mon, 06/3/19 - 08:17 pm
ASCO 2019
Celgene
Multiple Myeloma
Five Prime Therapeutics
Iovance
Merck
Moderna Therapeutics
Eli Lilly
ICR
Celgene gets FDA nod for blood cancer drug combo Revlimid plus rituximab
Pharmaceutical Business Review
Wed, 05/29/19 - 09:55 am
Celgene
Revlimid
follicular lymphoma
marginal zone lymphoma
Morphosys to take on CAR-Ts in NHL with promising antibody
Pharmaforum
Mon, 05/20/19 - 11:02 pm
MorphoSys
Celgene
Revlimid
non-Hodgkin lymphoma
clinical trials
tafasitamab
After years of delays, NICE backs Celgene’s Revlimid in first-line MM
Pharmaforum
Fri, 05/17/19 - 07:18 pm
Celgene
Revlimid
Multiple Myeloma
NICE
NHS
England
Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma
Pharmaceutical Business Review
Tue, 05/14/19 - 09:23 am
Celgene
Pomalyst
breakthrough therapies
Kaposi's Sarcoma
Biotech Companies Provide High Median Salaries, Analysis Shows
BioSpace
Thu, 05/9/19 - 11:07 pm
salaries
biotech
Incyte
Celgene
Vertex Pharmaceuticals
Don't worry about our $19B bond issue, BMS says. With Celgene, we'll have the cash to pay it off
Fierce Pharma
Wed, 05/8/19 - 05:18 pm
M&A
Bristol-Myers Squibb
Celgene
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »